{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:23:47Z","timestamp":1780496627226,"version":"3.54.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.562522","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T11:29:16Z","timestamp":1601033356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds"],"prefix":"10.3389","volume":"8","author":[{"given":"Kathrin","family":"Brockmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ana.20635","article-title":"Neuropathology of dementia in Parkinson\u2019s disease: a prospective, community-based study.","volume":"58","author":"Aarsland","year":"2005","journal-title":"Ann. Neurol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations.","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.parkreldis.2014.09.003","article-title":"Glucocerebrosidase mutations in primary parkinsonism.","volume":"20","author":"Asselta","year":"2014","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/jnnp-2019-320394","article-title":"Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study.","volume":"90","author":"Avenali","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/8904_2014_315","article-title":"Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.","volume":"16","author":"Barrett","year":"2014","journal-title":"JIMD Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson\u2019s disease.","volume":"30","author":"Berg","year":"2015","journal-title":"Mov. Disord."},{"key":"B8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mds.27659","article-title":"Parkinson\u2019s disease age at onset genome-wide association study: defining heritability, genetic loci, and alpha-synuclein mechanisms.","volume":"34","author":"Blauwendraat","year":"2019","journal-title":"Mov. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1212\/wnl.0000000000004705","article-title":"SNPs in Abeta clearance proteins: lower CSF Abeta1-42 levels and earlier onset of dementia in PD.","volume":"89","author":"Brockmann","year":"2017","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.parkreldis.2015.10.008","article-title":"Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study.","volume":"21","author":"Brockmann","year":"","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study.","volume":"30","author":"Brockmann","year":"","journal-title":"Mov. Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/wnl.0b013e318225ab77","article-title":"GBA-associated PD presents with nonmotor characteristics.","volume":"77","author":"Brockmann","year":"2011","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease.","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115747","article-title":"Glucocerebrosidase gene mutations associated with Parkinson\u2019s disease: a meta-analysis in a Chinese population.","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson\u2019s disease: the mutation matters.","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28112","article-title":"A Large-Scale Full GBA1 Gene Screening in Parkinson\u2019s Disease in the Netherlands.","author":"den Heijer","year":"2020","journal-title":"Mov Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies.","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/wnl.0b013e3181f61311","article-title":"What predicts mortality in Parkinson disease: a prospective population-based long-term study.","volume":"75","author":"Forsaa","year":"2010","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers.","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","article-title":"Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels.","volume":"121","author":"Gundner","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","article-title":"Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels.","volume":"121","author":"Gundner","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-008-0344-8","article-title":"The progression of pathology in longitudinally followed patients with Parkinson\u2019s disease.","volume":"115","author":"Halliday","year":"2008","journal-title":"Acta Neuropathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bcmd.2006.02.004","article-title":"Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.","volume":"36","author":"Halperin","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease.","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.parkreldis.2019.04.016","article-title":"Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia.","volume":"65","author":"Honeycutt","year":"2019","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000348","article-title":"Genetic risk of Parkinson disease and progression:: an analysis of 13 longitudinal cohorts.","volume":"5","author":"Iwaki","year":"2019","journal-title":"Neurol. Genet."},{"key":"B29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: etiopathogenesis and treatment.","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative study.","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/mds.27731","article-title":"Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.","volume":"34","author":"Lerche","year":"","journal-title":"Mov. Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/jnnp-2018-318956","article-title":"Parkinson\u2019s disease: evolution of cognitive impairment and CSF Abeta1-42 profiles in a prospective longitudinal study.","volume":"90","author":"Lerche","year":"","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/mds.27884","article-title":"Parkinson\u2019s disease: Glucocerebrosidase 1 mutation severity is associated with CSF Alpha-Synuclein profiles.","volume":"35","author":"Lerche","year":"2020","journal-title":"Mov. Disord."},{"key":"B34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease.","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B35","doi-asserted-by":"crossref","first-page":"156.e11","DOI":"10.1016\/j.neurobiolaging.2019.12.011","article-title":"Screening of the glucocerebrosidase (GBA) gene in South Africans of African ancestry with Parkinson\u2019s disease.","volume":"88","author":"Mahungu","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ane.12247","article-title":"Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson\u2019s disease - a systematic review.","volume":"130","author":"Malek","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"B37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","article-title":"Features of GBA-associated Parkinson\u2019s disease at presentation in the UK Tracking Parkinson\u2019s study.","volume":"89","author":"Malek","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies.","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/acn3.185","article-title":"Variants associated with Gaucher disease in multiple system atrophy.","volume":"2","author":"Mitsui","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson\u2019s disease.","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","article-title":"Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson\u2019s Disease and Dementia with Lewy Bodies.","volume":"56","author":"Moors","year":"2018","journal-title":"Mol Neurobiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","article-title":"Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson\u2019s Disease and Dementia with Lewy Bodies.","volume":"56","author":"Moors","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized. Noncontrolled Trial.","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease.","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease.","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cca.2019.03.1627","article-title":"Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies.","volume":"495","author":"Paciotti","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","article-title":"Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson\u2019s disease patients.","volume":"32","author":"Parnetti","year":"2017","journal-title":"Mov. Disord."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28195","article-title":"GBA-Related Parkinson\u2019s disease: dissection of genotype-phenotype correlates in a Large Italian Cohort.","author":"Petrucci","year":"2020","journal-title":"Mov Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature.","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov. Disord."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis.","volume":"5","author":"Schondorf","year":"2014","journal-title":"Nat. Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.wnl.0000345356.40399.eb","article-title":"Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy.","volume":"72","author":"Segarane","year":"2009","journal-title":"Neurology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a Biochemical Diagnosis of Parkinson Disease by Detection of alpha-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol."},{"key":"B54","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease.","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mdc3.12481","article-title":"Frequency of GBA variants in autopsy-proven multiple system atrophy.","volume":"4","author":"Sklerov","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"B56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies.","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/ene.12086","article-title":"No association of GBA mutations and multiple system atrophy.","volume":"20","author":"Srulijes","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-322857","article-title":"Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson\u2019s disease.","volume":"91","author":"Stoker","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jocn.2012.01.055","article-title":"Genetic association study of glucocerebrosidase gene L444P mutation in essential tremor and multiple system atrophy in mainland China.","volume":"20","author":"Sun","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.parkreldis.2018.05.009","article-title":"Parkinson\u2019s disease phenotype is influenced by the severity of the mutations in the GBA gene.","volume":"55","author":"Thaler","year":"2018","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.12.014","article-title":"A \u201cdose\u201d effect of mutations in the GBA gene on Parkinson\u2019s disease phenotype.","volume":"36","author":"Thaler","year":"2017","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13413-w","article-title":"LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients.","volume":"10","author":"Ysselstein","year":"2019","journal-title":"Nat. Commun."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00043","article-title":"Integrated genetic analysis of racial differences of common GBA variants in Parkinson\u2019s disease: a meta-analysis.","volume":"11","author":"Zhang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/ene.13776","article-title":"Patient\u2019s perception: shorter and more severe prodromal phase in GBA-associated PD.","volume":"26","author":"Zimmermann","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2017.12.012","article-title":"Reversible CONFORMATIONAL CONVERSION of alpha-Synuclein into toxic assemblies by glucosylceramide.","volume":"97","author":"Zunke","year":"2018","journal-title":"Neuron"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.562522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T04:41:06Z","timestamp":1617511266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.562522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":65,"alternative-id":["10.3389\/fcell.2020.562522"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.562522","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"article-number":"562522"}}